本组肝癌病人移植术后3年无复发生存率为100 ％ 。
研究者同时发现有28%的患者被预测为对治疗敏感，他们的3年无远处复发生存率为92%，绝对危险度大幅下降18%。
They also observed that in 28% of patients predicted to be sensitive to treatment, 3-year distant relapse-free survival (DRFS) was 92%, with a significant absolute risk reduction of 18%.
在治疗的第3年，雌激素受体阳性患者获得97%的无远处复发生存率，绝对危险度大幅下降11%。
At 3 years, ER-positive patients achieved a DRFS of 97% and a significant absolute risk reduction of 11%.
术后辅助内分泌治疗联合放疗的综合治疗可显著延长无生化复发生存时间。
Multi-modal treatment like adjuvant androgen deprivation therapy plus radiotherapy can greatly improve the biochemical recurrence-free survival.
术后辅助内分泌治疗联合放疗的综合治疗可显著延长无生化复发生存时间。
Multi-modal treatment like adjuvant androgen deprivation therapy plus radiotherapy can greatly improve the biochemical recurrence-free survival.
应用推荐